The U.S. FDA approved AbbVie’s oral Parkinson’s disease therapy Juvmo (tavapadon), a selective D1/D5 receptor agonist with partial agonist activity at D1/D4. AbbVie positioned the drug as a first-in-class approach, including a dosing schedule designed for adults with Parkinson’s disease either as monotherapy with or without levodopa. AbbVie said Juvmo is expected to be available to adult PD patients next month, expanding treatment options beyond existing dopaminergic and adjunctive regimens. The approval also reflects the post-buyout integration of Cerevel Therapeutics’ assets into AbbVie’s neurology strategy following the 2024 acquisition.